Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHESAHNA KINDRED WEAVER

Allopathic & Osteopathic Physicians Dermatology

NPI
1518193630
CMS profile
160023
Location
MARRIOTTSVILLE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$31,613.55

93 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–93 of 93 matching records. This page contains 43 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHESAHNA KINDRED WEAVER

NPI 1518193630 · CMS profile ID 160023

Allopathic & Osteopathic Physicians / Dermatology

MARRIOTTSVILLE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–93 of 93 matching records. This page contains 43 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1518193630?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHESAHNA KINDRED WEAVER, NPI 1518193630, CMS profile ID 160023. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–93 of 93 matching records. This page contains 43 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518193630?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). CHESAHNA KINDRED WEAVER, NPI 1518193630, CMS profile ID 160023. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–93 of 93 matching records. This page contains 43 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518193630?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
CHESAHNA KINDRED WEAVER, NPI 1518193630, CMS profile ID 160023, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–93 of 93 matching records. This page contains 43 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1518193630?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

93 matching records · $31,613.55 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 93 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–93 of 93.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
LEO Pharma Inc. $27.3705/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842215091 CMS
AbbVie Inc. $0.9205/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795106943 CMS
AbbVie Inc. $18.1605/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795106939 CMS
Lilly USA, LLC $2,012.5005/14/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819018037 CMS
Novartis Pharmaceuticals Corporation $12.4905/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812752211 CMS
AbbVie Inc. $3.6305/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795106935 CMS
UCB, Inc. $2,250.0005/06/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807398797 CMS
Lilly USA, LLC $21.1005/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818901359 CMS
Almirall LLC $23.3704/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819690901 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $9,170.0004/23/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851869129 CMS
PFIZER INC. $21.0304/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832709297 CMS
AbbVie Inc. $18.7504/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795106931 CMS
VYNE Pharmaceuticals Inc. $21.0204/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830827397 CMS
Novartis Pharmaceuticals Corporation $12.6404/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812752209 CMS
Janssen Biotech, Inc. $19.4804/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788336835 CMS
UCB, Inc. $14.5704/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807344527 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $14.1404/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851869119 CMS
GENZYME CORPORATION $21.1704/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843604555 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $15.2504/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851869135 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $1.2503/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851869121 CMS
AbbVie Inc. $2.8103/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795106927 CMS
AbbVie Inc. $16.4603/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795106923 CMS
Novartis Pharmaceuticals Corporation $17.7103/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812752207 CMS
Janssen Biotech, Inc. $17.2603/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788336833 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $19.1603/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851869111 CMS
UCB, Inc. $6.8203/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807301211 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $3,552.0003/10/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851869127 CMS
Lilly USA, LLC $26.8703/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819018045 CMS
UCB, Inc. $23.3502/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807303197 CMS
UCB, Inc. $6.6702/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807320875 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $13.3802/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851869109 CMS
AbbVie Inc. $22.5002/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795106919 CMS
VYNE Pharmaceuticals Inc. $24.2902/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830816299 CMS
DERMIRA, INC. $17.5402/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 764400316 CMS
Novartis Pharmaceuticals Corporation $20.9901/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812752205 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $22.5101/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851869115 CMS
AbbVie Inc. $13.0501/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795106917 CMS
Galderma Laboratories, L.P. $21.1601/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855284569 CMS
UCB, Inc. $7.0601/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807295865 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $5.5301/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851869113 CMS
Lilly USA, LLC $16.7301/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819004205 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $21.0201/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851869147 CMS
AbbVie Inc. $23.1201/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795106911 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,277.29 84
PY2020 $5,268.75 55
PY2021 $31,613.55 93
PY2022 $125,532.21 201
PY2023 $186,284.69 279
PY2024 $246,326.81 324
PY2025 $240,135.64 312

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,270.00 2
PY2025 Principal investigator $205,235.87 176
PY2024 Recipient $3,205.64 15
PY2024 Principal investigator $273,834.27 88
PY2023 Recipient $8,500.00 1
PY2023 Principal investigator $40,489.18 17
PY2022 Principal investigator $14,500.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

178 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,529.40 12/31/2025 Non-covered Recipient Entity
RAVEN CLINICAL RESEARCH
A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata No dispute reported 06/30/2026 1202533169
Principal investigator 1 Incyte Corporation $52.14 12/01/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512878
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512912
Principal investigator 1 Incyte Corporation $22.90 12/01/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512925
Principal investigator 1 Incyte Corporation $11.45 12/01/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512930
Principal investigator 1 Incyte Corporation $2,078.00 11/21/2025 Non-covered Recipient Entity
RAVEN CLINICAL RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240580308
Principal investigator 1 Incyte Corporation $2,078.00 11/21/2025 Non-covered Recipient Entity
RAVEN CLINICAL RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240580312
Principal investigator 1 PFIZER INC. $1,323.00 11/19/2025 Non-covered Recipient Entity
RAVEN CLINICAL RESEARCH INC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228807969
Principal investigator 1 PFIZER INC. $1,323.00 11/19/2025 Non-covered Recipient Entity
RAVEN CLINICAL RESEARCH INC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228807975
Principal investigator 1 Novartis Pharmaceuticals Corporation $84.16 11/15/2025 Non-covered Recipient Entity
CARE ACCESS MARRIOTTSVILLE
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S No dispute reported 06/30/2026 1190312873
Principal investigator 1 Incyte Corporation $5,000.00 11/12/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512890
Principal investigator 1 Incyte Corporation $1,000.00 11/12/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512900
Principal investigator 1 Incyte Corporation $28.00 11/12/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512904
Principal investigator 1 Incyte Corporation $1,500.00 11/12/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512922
Principal investigator 1 Incyte Corporation $286.00 11/12/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512934
Principal investigator 1 Incyte Corporation $2,544.00 11/10/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512882
Principal investigator 1 Incyte Corporation $2,544.00 11/10/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512886
Principal investigator 1 ABBVIE INC. $4,275.40 11/05/2025 Non-covered Recipient Entity
RAVEN CLINICAL RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202523047
Principal investigator 1 PFIZER INC. $12,694.00 11/04/2025 Non-covered Recipient Entity
Raven Clinical Research Inc
A LONGTERM DOUBLEBLIND EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN PARTICIPANTS WITH SEVERE ALOPECIA AREATA WHO PREVIOUSLY COMPLETED STUDIES B7981027 OR B7981031 No dispute reported 06/30/2026 1228818122
Principal investigator 1 Incyte Corporation $15,500.00 10/09/2025 Non-covered Recipient Entity
RAVEN CLINICAL RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240580304
Principal investigator 1 Incyte Corporation $1,817.00 10/08/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512938
Principal investigator 1 Incyte Corporation $28.00 10/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512870
Principal investigator 1 Incyte Corporation $42.00 10/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512874
Principal investigator 1 Incyte Corporation $90.00 10/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512893
Principal investigator 1 Incyte Corporation $350.00 10/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512897
Principal investigator 1 Incyte Corporation $54.00 10/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512908
Principal investigator 1 Incyte Corporation $286.00 10/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512918
Principal investigator 1 PFIZER INC. $12,694.00 09/24/2025 Non-covered Recipient Entity
Raven Clinical Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1228828489
Principal investigator 1 ABBVIE INC. $925.74 09/16/2025 Non-covered Recipient Entity
RAVEN CLINICAL RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202511070
Principal investigator 1 Incyte Corporation $286.00 09/12/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512743
Principal investigator 1 Incyte Corporation $250.00 09/12/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512754
Principal investigator 1 Incyte Corporation $360.00 09/12/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512761
Principal investigator 1 Incyte Corporation $162.00 09/12/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512772
Principal investigator 1 Incyte Corporation $168.00 09/12/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512776
Principal investigator 1 Incyte Corporation $76.00 09/12/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512779
Principal investigator 1 Incyte Corporation $14.00 09/12/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512784
Principal investigator 1 Incyte Corporation $729.00 09/12/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512798
Principal investigator 1 ABBVIE INC. $5,568.10 09/04/2025 Non-covered Recipient Entity
RAVEN CLINICAL RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202509108
Principal investigator 1 Incyte Corporation $3,000.00 08/20/2025 Non-covered Recipient Entity
RAVEN CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240580300
Principal investigator 1 ABBVIE INC. $347.50 08/14/2025 Non-covered Recipient Entity
RAVEN CLINICAL RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202504779
Principal investigator 1 ABBVIE INC. $2,103.07 08/14/2025 Non-covered Recipient Entity
RAVEN CLINICAL RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202504793
Principal investigator 1 Incyte Corporation $62.27 08/04/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512789
Principal investigator 1 Incyte Corporation $10.60 08/04/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512793
Principal investigator 1 Incyte Corporation $32.88 08/04/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512802
Principal investigator 1 Incyte Corporation $49.36 08/04/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512805
Principal investigator 1 Incyte Corporation $59.13 08/04/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512808
Principal investigator 1 Incyte Corporation $54.76 08/04/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512812
Principal investigator 1 Incyte Corporation $45.80 08/04/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512816
Principal investigator 1 Incyte Corporation $32.36 08/04/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512820
Principal investigator 1 Incyte Corporation $1,817.00 08/04/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512824
Principal investigator 1 Incyte Corporation $1,817.00 08/04/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512828
Principal investigator 1 Incyte Corporation $135.40 08/04/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512831
Principal investigator 1 Incyte Corporation $32.88 08/04/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512852
Principal investigator 1 Incyte Corporation $32.88 08/04/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512862
Principal investigator 1 Incyte Corporation $32.88 08/04/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512866
Principal investigator 1 Incyte Corporation $1,203.46 08/01/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512645
Principal investigator 1 Incyte Corporation $28.00 08/01/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512648
Principal investigator 1 Incyte Corporation $1,817.00 07/09/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512655
Principal investigator 1 Incyte Corporation $858.00 07/09/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512662
Principal investigator 1 Incyte Corporation $54.00 07/09/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512668
Principal investigator 1 Incyte Corporation $243.00 07/09/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512673
Principal investigator 1 Incyte Corporation $42.00 07/09/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512679
Principal investigator 1 Incyte Corporation $270.00 07/09/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512686
Principal investigator 1 Incyte Corporation $572.00 07/09/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512693
Principal investigator 1 Incyte Corporation $168.00 07/09/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512697
Principal investigator 1 Incyte Corporation $500.00 07/09/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512702
Principal investigator 1 Incyte Corporation $500.00 07/09/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512709
Principal investigator 1 Incyte Corporation $2,484.00 07/09/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512714
Principal investigator 1 Incyte Corporation $56.00 07/09/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512720
Principal investigator 1 Incyte Corporation $90.00 07/09/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512727
Principal investigator 1 Incyte Corporation $3,000.00 07/09/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512733
Principal investigator 1 Incyte Corporation $750.00 07/09/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512738
Principal investigator 1 Incyte Corporation $54.00 07/09/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512749
Principal investigator 1 Incyte Corporation $56.00 07/09/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512765
Principal investigator 1 Incyte Corporation $90.00 07/09/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512769
Principal investigator 1 Incyte Corporation $162.00 07/09/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512836
Principal investigator 1 Incyte Corporation $286.00 07/09/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512839
Principal investigator 1 Incyte Corporation $28.00 07/09/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512842
Principal investigator 1 Incyte Corporation $1,817.00 07/09/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512846
Principal investigator 1 Incyte Corporation $500.00 07/09/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512850
Principal investigator 1 SANOFI US SERVICES INC. $5,250.00 07/02/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112461
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 07/02/2025 Non-covered Recipient Entity
UNITED CLINICAL RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223282180
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 07/02/2025 Non-covered Recipient Entity
UNITED CLINICAL RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223282190
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 06/25/2025 Non-covered Recipient Entity
UNITED CLINICAL RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223281892
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,683.02 06/15/2025 Non-covered Recipient Entity
KINDRED HAIR AND SKIN CENTER
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1190308866
Principal investigator 1 Incyte Corporation $1,817.00 06/06/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512387
Principal investigator 1 Incyte Corporation $575.46 06/04/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512397
Principal investigator 1 Incyte Corporation $162.00 06/04/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512403
Principal investigator 1 Incyte Corporation $72.00 06/04/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512410
Principal investigator 1 Incyte Corporation $139.00 06/04/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512417
Principal investigator 1 Incyte Corporation $572.00 06/04/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512424
Principal investigator 1 Incyte Corporation $152.00 06/04/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512430
Principal investigator 1 Incyte Corporation $486.00 06/04/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512436
Principal investigator 1 Incyte Corporation $210.00 06/04/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512559
Principal investigator 1 Incyte Corporation $270.00 06/04/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512639
Principal investigator 1 ABBVIE INC. $4,595.10 06/03/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202489205
Principal investigator 1 Incyte Corporation $3.10 06/03/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512472
Principal investigator 1 Incyte Corporation $8.22 06/03/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512482
Principal investigator 1 Incyte Corporation $82.20 06/03/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512507
Principal investigator 1 Incyte Corporation $82.20 06/03/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512547
Principal investigator 1 Incyte Corporation $24.30 06/03/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512554
Principal investigator 1 Incyte Corporation $246.80 06/03/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512570
Principal investigator 1 Incyte Corporation $2.43 06/03/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512586
Principal investigator 1 Incyte Corporation $8.22 06/03/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512598
Principal investigator 1 Incyte Corporation $8.22 06/03/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512603
Principal investigator 1 Incyte Corporation $8.22 06/03/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512609
Principal investigator 1 Incyte Corporation $82.20 06/03/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512614
Principal investigator 1 Incyte Corporation $82.20 06/03/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512622
Recipient PFIZER INC. $940.00 05/30/2025 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228828881
Principal investigator 1 ABBVIE INC. $83.53 05/27/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202486285
Principal investigator 1 ABBVIE INC. $1,000.00 05/27/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202486287
Principal investigator 1 SANOFI US SERVICES INC. $4,500.00 05/27/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113301
Principal investigator 1 ABBVIE INC. $4,953.00 05/07/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202484059
Principal investigator 1 Incyte Corporation $1,817.00 05/07/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512357
Recipient PFIZER INC. $330.00 05/07/2025 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228828951
Principal investigator 1 Incyte Corporation $24.68 05/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512486
Principal investigator 1 Incyte Corporation $62.27 05/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512492
Principal investigator 1 Incyte Corporation $62.27 05/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512498
Principal investigator 1 Incyte Corporation $0.31 05/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512504
Principal investigator 1 Incyte Corporation $17.01 05/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512513
Principal investigator 1 Incyte Corporation $148.85 05/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512518
Principal investigator 1 Incyte Corporation $54.76 05/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512524
Principal investigator 1 Incyte Corporation $54.76 05/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512529
Principal investigator 1 Incyte Corporation $64.72 05/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512537
Principal investigator 1 Incyte Corporation $64.72 05/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512542
Principal investigator 1 Incyte Corporation $160.30 05/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512591
Principal investigator 1 Incyte Corporation $19.44 05/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512627
Principal investigator 1 Incyte Corporation $2.43 05/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512632
Principal investigator 1 Incyte Corporation $83.00 04/23/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512311
Principal investigator 1 Incyte Corporation $108.00 04/23/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512321
Principal investigator 1 Incyte Corporation $112.00 04/23/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512325
Principal investigator 1 Incyte Corporation $750.00 04/23/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512332
Principal investigator 1 Incyte Corporation $42.00 04/23/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512366
Principal investigator 1 Incyte Corporation $180.00 04/23/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512375
Principal investigator 1 Incyte Corporation $286.00 04/23/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512575
Principal investigator 1 Incyte Corporation $450.00 04/18/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512338
Principal investigator 1 Incyte Corporation $1,500.00 04/18/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512580
Principal investigator 1 ABBVIE INC. $500.00 04/15/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202476539
Principal investigator 1 Incyte Corporation $572.00 04/07/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512306
Principal investigator 1 Incyte Corporation $126.00 04/07/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512318
Principal investigator 1 Incyte Corporation $180.00 04/07/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512345
Principal investigator 1 Incyte Corporation $1,971.00 04/07/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512351
Principal investigator 1 Incyte Corporation $108.00 04/07/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512381
Principal investigator 1 Incyte Corporation $262.00 04/07/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512565
Principal investigator 1 Janssen Research & Development, LLC $8,044.00 04/04/2025 Non-covered Recipient Entity
Care Access Rsrch Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175225787
Principal investigator 1 ABBVIE INC. $500.00 04/03/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202471777
Principal investigator 1 ABBVIE INC. $4,003.20 04/03/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202471781
Principal investigator 1 Incyte Corporation $26.90 04/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512443
Principal investigator 1 Incyte Corporation $21.52 04/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512448
Principal investigator 1 Incyte Corporation $148.40 04/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512455
Principal investigator 1 Incyte Corporation $365.70 04/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512461
Principal investigator 1 Incyte Corporation $75.32 04/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512466
Principal investigator 1 Incyte Corporation $84.80 04/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512477
Principal investigator 1 ABBVIE INC. $150.12 03/25/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202465800
Principal investigator 1 Eli Lilly and Company $1,084.80 03/25/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187877211
Principal investigator 1 Incyte Corporation $1,917.00 03/12/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512233
Principal investigator 1 Incyte Corporation $1,971.00 03/12/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512250
Principal investigator 1 ABBVIE INC. $10,925.40 03/07/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202461431
Principal investigator 1 ABBVIE INC. $36.14 02/24/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202453653
Principal investigator 1 Incyte Corporation $1,953.00 02/19/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512238
Principal investigator 1 Incyte Corporation $2,742.00 02/19/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512261
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,414.88 02/01/2025 Non-covered Recipient Entity
CARE ACCESS MARRIOTTSVILLE
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S No dispute reported 06/30/2026 1190312875
Principal investigator 1 Novartis Pharmaceuticals Corporation $12,000.00 01/21/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S No dispute reported 06/30/2026 1190311135
Principal investigator 1 Incyte Corporation $1,817.00 01/17/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512211
Principal investigator 1 Incyte Corporation $1,917.00 01/17/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512222
Principal investigator 1 Incyte Corporation $1,953.00 01/17/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512244
Principal investigator 1 PFIZER INC. $5,000.00 01/17/2025 Non-covered Recipient Entity
RAVEN CLINICAL RESEARCH INC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228713842
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 01/13/2025 Non-covered Recipient Entity
Care Access Rsrch Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175226645
Principal investigator 1 Incyte Corporation $3.41 01/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512216
Principal investigator 1 Incyte Corporation $41.10 01/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512227
Principal investigator 1 Incyte Corporation $68.70 01/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512255
Principal investigator 1 Incyte Corporation $34.02 01/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512265
Principal investigator 1 Incyte Corporation $41.10 01/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512271
Principal investigator 1 Incyte Corporation $123.40 01/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512279
Principal investigator 1 Incyte Corporation $97.08 01/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512286
Principal investigator 1 Incyte Corporation $41.10 01/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512291
Principal investigator 1 Incyte Corporation $41.10 01/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512297
Principal investigator 1 Incyte Corporation $1,083.20 01/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240512300